The Korean pharmaceutical and biotech industry has obtained a minimal buffer period concerning price reductions linked to the re‑evaluation of listed medicines.
Initially, the sector warned that large‑scale price cuts could directly diminish profitability, curb R&D investment, lead to reductions in production facilities and staff, and jeopardize the commercial viability of certain products.
Through ongoing discussions on detailed criteria, the government, the Korean Pharmaceutical Bio Association and industry representatives have postponed the implementation timeline and introduced realistic standards for combination‑drug price cuts, reflecting some of the industry's demands.
The adjustments are aimed at innovative and semi‑innovative pharmaceutical companies.
規制動向2026年9月15日•3分で読めます
Korean Pharma Secures Minimal Buffer Amid Drug Price Cut Reassessment
The Korean pharmaceutical and biotech sector has secured a limited buffer period as the government delays and adjusts price‑cut criteria for re‑evaluated listed drugs.
Pharmacountryチームがまとめました · 出典： KPA News
トピック：
評価
(0)
(0)
(0)
(0)
(0)
評価を残す